RECQL1 as a potential therapeutic target for PARP inhibitor-resistant ovarian cancer.

Sci Rep · 2025 · PMC12575764 · PMID 41168257

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

did not reach statistical significanceP = 0.09so close (0.05 < p ≤ 0.1)

Although high RECQL1 expression also tended to be associated with worse PFS, this trend did not reach statistical significance (HR: 1.93; 95% CI: 0.91–4.47; P = 0.09).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.